

Table S3. Binding predictions for known class I epitopes in the core region to common South African alleles

Allele	Start	End	Length	Peptide (genotype 1a)	Method used	Percentile rank	ANN IC50(nM)	Ref
HLA-A*02:01	132	140	9	DLMGYIPLV	Consensus (ann/smm/comblib_sidney2008)	0.3	6	Wedemeyer et al., 2009
HLA-B*07:02	41	49	9	GPRLGVRAT	Consensus (ann/smm/comblib_sidney2008)	0.4	19	Zeng et al., 2009
HLA-A*02:01	29	37	9	QIVGGVYLL	Consensus (ann/smm/comblib_sidney2008)	3.3	232	Zeng et al., 2009
HLA-A*30:01	45	53	9	GVRATRKTS	Consensus (ann/smm/comblib_sidney2008)	4.9	216	Zeng et al., 2009
HLA-B*07:02	111	119	9	DPRRRSRNL	Consensus (ann/smm/comblib_sidney2008)	0.5	24	Zeng et al., 2009
HLA-B*07:02	169	177	9	LPGCSFSIF	Consensus (ann/smm/comblib_sidney2008)	1.4	173	Zeng et al., 2009
DRB1*03:01	96	104	9	WLLSPRGSR	Consensus (ann/smm/comblib_sidney2008)	0.02	98 (SMM, IC50nm)	Day et al., 2002

References

Day, C.L., Lauer, G.M., Robbins, G.K., McGovern, B., Wurcel, A.G., Gandhi, R.T., Chung, R.T., Walker B.D., 2002. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection, *J. Virol.* **76**, 12584–12595.

Wedemeyer, H., Schuller, E., Schlaphoff, V., Stauber, R.E., Wiegand, J., Schiefke, I., Firbas, C., Jilma, B., Thursz, M., Zeuzem, S., Hofmann, W.P., Hinrichsen, H., Tauber, E., Manns, M.P., Klade C.S., 2009. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C, *Vaccine* **27**, 5142–5151.

Zeng, R., Li, G., Ling, S., Zhang, H., Yao, Z., Xiu, B., He, F., Huang, R., Wei, L., 2009. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice, *Antivir. Res.* **84**, 23–30.